Context: Diet and beverages are thought to have notable effects on drugs. Recently, this relationship has received significant consideration.

Aims: To develop and validate a simple, rapid, and sensitive method for the determination of glimepiride in rat serum. This will be performed using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Potential pharmacokinetic interactions between glimepiride and the soft drink, Vimto, will also be investigated in the serum of experimental rats.

Materials And Methods: HPLC-MS/MS was constructed and clarithromycin was used as an internal standard.

Results: The method was validated in terms of linearity, precision, accuracy, stability, and system suitability parameters. The method was found to be satisfactory and suitable for the determination of glimepiride. The precision of glimepiride was high (coefficient of variation, CV% <15%), the accuracy over all 3 days of validation was within the accepted criteria. Glimepiride peak serum concentration ( ) was 126.01 ng/mL and was reached within 1 h ( ) of administration. Mean area under curve (AUC) was 964.70 ng/mL and was reached within 24 h of administration. The Vimto soft drink significantly ( < 0.050) reduced glimepiride peak serum concentration to 57.87 ng/mL and was reached within 2 h of administration. AUC was significantly reduced to 335.04 ngh/mL ( < 0.050).

Conclusion: Glimepiride pharmacokinetic parameters such as and AUC were significantly affected by the Vimto soft drink. Therefore, this study developed a simple, rapid, and sensitive method for validation and determination of the effects of soft drinks on drugs using the LC-MS/MS method.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394163PMC
http://dx.doi.org/10.4103/jpbs.JPBS_200_18DOI Listing

Publication Analysis

Top Keywords

determination glimepiride
12
method determination
8
glimepiride
5
development validation
4
validation liquid
4
liquid chromatography
4
method
4
chromatography method
4
glimepiride presence
4
presence vimto
4

Similar Publications

Background: Uncontrolled diabetes persists despite guideline-based treatment, partly attributed to inadequate patient involvement. This research addresses shared decision-making by eliciting patient preferences in Type 2 Diabetes Mellitus (T2DM) treatment based on certain key attributes and explores their correlation with socio-demographic-clinical profiles.

Methods: A discrete choice experiment (DCE) was conducted among T2DM outpatients in an Indian tertiary care center.

View Article and Find Full Text PDF

Background: Long-term metabolic disease type 2 diabetes mellitus (T2DM) is distinguished by elevated blood glucose, insulin resistance, and drought of insulin with dyslipidemia. Oral hypoglycemic agents lower blood glucose levels as well as prevent both short-term and long-term complications such as micro/macrovascular atherosclerosis, chronic kidney diseases, and chronic heart disease. This study aims to compare the effect of glimepiride versus teneligliptin in combination with metformin in T2DM patients attending a tertiary care hospital.

View Article and Find Full Text PDF

Carnitine O-acetyltransferase (CRAT) is a crucial enzyme involved in mitochondrial energy metabolism. Alterations in CRAT activity have emerged as significant contributors to the pathogenesis of Leigh syndrome and related mitochondrial disorders. In this study we employed an integrated approach combining in silico docking analysis and virtual screening of chemical libraries with subsequent in vitro validation to identify small molecule modulators of the activity of the wild type (WT) CRAT and the p.

View Article and Find Full Text PDF

Aligned with the mission of the Dutch Pharmacogenetics Working Group (DPWG) to promote the implementation of pharmacogenetics (PGx), this guideline is specifically designed to optimize pharmacotherapy of cholesterol lowering medication (statins) and glucose lowering medication (sulfonylureas). The SLCO1B1 c.521 T > C variant reduces the activity of the SLCO1B1 transporter involved in statin transport out of the blood into the liver.

View Article and Find Full Text PDF

Sustained release of nano-encapsulated glimepiride drug with chitosan nanoparticles: A novel approach to control type 2 diabetes in streptozotocin-induced Wistar albino rats.

Int J Biol Macromol

December 2024

Unit of Nanotechnology and Bioactive Natural Products, Post Graduate and Research Department of Zoology, C. Abdul Hakeem College (Autonomous), Melvisharam - 632 509, Ranipet District (Affiliated to Thiruvalluvar University, Vellore), Tamil Nadu, India.

The objective of the present study was to encapsulate the effective antidiabetic glimepiride (GLM) drug with biodegradable chitosan nanoparticles (CS NPs) in order to reduce the risk of side effects, regulate and improve alternatives to therapy for people with type 2 Diabetes mellitus. The characterizations of the encapsulated EGLM-CS NPs were published in a previous paper. In continuation of the past study, here we report the in vitro and in vivo activities of EGLM-CS NPs in streptozotocin-induced diabetes Wistar albino rats orally treated for 28 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!